The treatment of Parkinson's disease with levodopa has been discussed in a recent study from the Henry Ford Hospital in Detroit, USA.

Dr Peter A LeWitt, a neurologist at the medical institution, has had his latest comments published in the December 4th edition of the New England Journal of Medicine - and has taken the opportunity to heap praise on the drug.

He states that levodopa is not only an effective solution for the treatment of both early and advanced stages of Parkinson's, but can also be utilised to confirm suspected cases of the disease.

"Within a few minutes after taking an oral dose of levodopa, a patient can recover from previous impairments in speech, dexterity and gait," he notes.

In addition, Dr LeWitt suggests levodopa treatment can be easily postponed where symptoms are "mild and tolerable", but adds the drug could be the exclusive option in limiting patient discomfort in such cases.

Staff at the University of Ottawa Heart Institute in Canada recently examined the subcellular location of Parkin - the product of the Parkinson's disease-related gene Park2 - to learn about the role of the protein in cell cytoplasm.

Login and visit the Parkinson's Disease Knowledge Centre

• Mice could hold key to understanding non-motor Parkinson's symptoms 03/07/09
• Enzyme helps to destroy mutated protein associated with Parkinson's 26/06/09
• Study investigates addictions in Parkinson's disease patients 26/02/09
• New Parkinson's drug is 'safe and well-tolerated' in humans 04/02/09
• Protein could protect against Parkinson's-causing chemical 03/02/09

• NEUPRO Transdermal Patch - 83.51%
  ... treatment of moderate to severe idiopathic Restless Legs Syndrome in adults. Parkinson's disease Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course ...
  
  
• DATSCAN 74 MBq/ml solution for injection - 83.51%
  ... in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. DaTSCAN is unable to discriminate between Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy ...
  
  
• Parlodel 10 mg capsules - 83.51%
  ... to surgery and/or radiotherapy to reduce circulating growth hormone in the management of acromegalic patients. Parkinson's Disease : In the treatment of idiopathic Parkinson's Disease, PARLODEL has been used both alone and in combination with Levodopa in the management of previously treated patients ...
  
  
• PARLODEL 1 mg Tablets - 83.51%
  ... to surgery and/or radiotherapy to reduce circulating growth hormone in the management of acromegalic patients. Parkinson's Disease : In the treatment of idiopathic Parkinson's Disease, PARLODEL has been used both alone and in combination with Levodopa in the management of previously untreated ...
  
  
• REQUIP - 83.51%
  Treatment of idiopathic Parkinson's Disease : Ropinirole may be used alone (without levodopa) in the treatment of idiopathic Parkinson's disease . Addition of ropinirole to levodopa may be used to control "on-off" fluctuations and permit a reduction in the total daily dose of levodopa ...
  
  
• CABASER - 83.51%
  Treatment of Parkinson's disease If treatment with a dopamine agonist is being considered, cabergoline is indicated as second line therapy in patients who are intolerant or fail treatment with a non-ergot compound, as monotherapy, or as adjunctive treatment to levodopa plus dopa-decarboxylase ...